Last reviewed · How we verify
L-CARNOSINE
At a glance
| Generic name | L-CARNOSINE |
|---|---|
| Also known as | CARNOSINE, Carnosine, L Carnosine |
| Sponsor | Cairo University |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes (NA)
- Nucleophilic Defense Against PM Toxicity (NEAT Trial) (NA)
- Effects of Carnosine In Patients With Peripheral Arterial Disease Patients (PHASE1,PHASE2)
- Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease (NA)
- Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity (NA)
- Polaprezinc (Zinc L-carnosine) in Infants With Gastroesophageal Reflux (NA)
- Carnosine for Peripheral Arterial Disease Patients (PHASE1,PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-CARNOSINE CI brief — competitive landscape report
- L-CARNOSINE updates RSS · CI watch RSS
- Cairo University portfolio CI